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Abstract
Background: The anterior cingulate cortex (ACC) is a key structure of the pain processing network. Several structural and
functional alterations of this brain area have been found in migraine. In addition, altered serotonergic neurotransmission
has been repeatedly implicated in the pathophysiology of migraine, although the exact mechanism is not known. Thus,
our aim was to investigate the relationship between acute increase of brain serotonin (5-HT) level and the activation
changes of the ACC using pharmacological challenge MRI (phMRI) in migraine patients and healthy controls.
Methods: Twenty-seven pain-free healthy controls and six migraine without aura patients participated in the study. All
participant attended to two phMRI sessions during which intravenous citalopram, a selective serotonin reuptake inhibitor
(SSRI), or placebo (normal saline) was administered. We used region of interest analysis of ACC to compere the citalopram
evoked activation changes of this area between patients and healthy participants.
Results: Significant difference in ACC activation was found between control and patient groups in the right pregenual
ACC (pgACC) during and after citalopram infusion compared to placebo. The extracted time-series showed that pgACC
activation increased in migraine patients compared to controls, especially in the first 8–10min of citalopram infusion.
Conclusions: Our results demonstrate that a small increase in 5-HT levels can lead to increased phMRI signal in the
pregenual part of the ACC that is involved in processing emotional aspects of pain. This increased sensitivity of the
pgACC to increased 5-HT in migraine may contribute to recurring headache attacks and increased stress-sensitivity in
migraine.
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Article highlights or key findings
 Current citalopram challenge pharmacological MRI
study confirmed that migraine patients are more
sensitive to the acute elevation of synaptic serotonin
level.
 Citalopram challenge (e.g. acutely increased brain
serotonin level) led to increased fMRI signal in the
pregenual anterior cingulate cortex in migraine
patients compared to controls, which is an
important area processing emotional aspects of pain.
 As serotonin level shows temporary increase during
migraine attacks, our results suggest that increased
pregenual anterior cingulate cortex activation may
contribute to the suffering element of migraine pain.
Background
The anterior cingulate cortex (ACC) is a key structure of
the pain processing network [1] as it is involved in de-
scending pain modulation, attention to pain [2], emo-
tional dimensions of pain and has also been implicated
in the pathophysiology of pain related disorders [3]. Im-
portant structural and functional alterations have been
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found in this brain area in case of experimental headache,
medication-overuse headache, tension-type headache and
migraine [4]. A recent meta-analysis of grey matter
changes in migraine showed a grey matter volume de-
crease in the ACC associated with headache frequency [5].
However, the specificity of grey matter changes in this
region is questionable as this phenomenon has been ob-
served in several other psychiatric and neurologic condi-
tions [6]. Previous whole brain functional MRI (fMRI)
analysis showed increased brain activation during noxious
trigeminal heat stimulation specifically in the ACC in mi-
graine patients compared to healthy controls [7]. How-
ever, another study with similar method did not find any
differences between the two groups [8].
Animal studies have demonstrated that activation of
excitatory synapsis in the ACC facilitate pain perception
and increase the sensitivity to unpleasantness of pain [9],
specifically, glutamatergic projections from the ACC en-
hance spinal sensory transmission which have been
shown to amplify pain [10]. This excitatory neurotrans-
mission in the ACC is modulated by serotonin, namely
serotonin (5-HT, 5-hydroxytryptamine) inhibits the re-
lease of glutamate [11]. In line with these animal studies,
subchronic administration of escitalopram, a selective
serotonin reuptake inhibitor (SSRI), in humans led to
decreased activation of the ventral ACC during anticipa-
tion of aversive vs. pleasant images in healthy subjects
[12]. In addition, 7 days of fluvoxamine treatment in
healthy individuals led to decreased regional cerebral
blood flow in the ACC during painful stimuli [13]. These
observations show the impact of serotonergic neuro-
transmission on the ACC functions and on correspond-
ing pain modulation.
5-HT has been implicated in migraine pathophysiology
for a long time. Several studies have found increased
urinary 5-HT metabolite 5-hydoxyindoleacetic acid (5-
HIAA) levels in migraine patients ictally [14, 15]. One
study showed increased levels of 5-HIAA in cerebro-
spinal fluid in migraineurs during attacks [16]. In
addition, interictally decreased plasma 5-HT levels were
also observed in migraine patients [17–21]. These early
observations of the altered serotonergic neurotransmis-
sion were the basis of the idea that migraine is charac-
terized with chronically low 5-HT levels and with a
temporary increase during headache. However, PET
studies previously reported increased 5-HT brain levels
indexed by 5-HT4 receptor binding in episodic [22, 23]
and chronic [23] migraine patients, therefore the theory
of low 5-HT levels in migraine has been questioned.
Serotonergic challenge is a method widely used to in-
vestigate the effect of acute increases in 5-HT level or
serotonergic receptor activation due to administration of
a serotonergic agent [24, 25]. Reserpine, fenfluramine
and m-chlorophenylpiperazine (mCPP) are widely used
to investigate serotonergic neurotransmission, however,
these drugs often provoke headache in migraine patients
[24]. SSRIs are able to increase brain 5-HT levels, have lit-
tle affinity to other receptors [26] and rarely provoke
headache in migraine [21]. Citalopram is one of the most
selective SSRIs [27] and it is the only SSRI available in
intravenous form, which is favored to avoid pharmacoki-
netic issues during the challenge. For this reason, we
chose citalopram drug challenge to investigate serotoner-
gic neurotransmission in migraine patients interictally.
The aim of our study was to investigate the acute
effect of increased synaptic serotonergic levels evoked by
citalopram on the ACC in migraine patients. We used
subtherapeutic dose of citalopram for a drug challenge
with fMRI (citalopram challenge pharmacoMRI, citalo-
pram phMRI) to study the citalopram induced changes
in the ACC activation in migraine patients and healthy
subjects. We hypothesized that migraine patients would
be more sensitive to the acute elevation of cortical 5-HT
levels and this altered sensitivity will be shown by activa-
tion changes of the above mentioned important pain
control area, the ACC.
Methods
Participants
Twenty-seven pain-free healthy participants (15 women,
mean [SD] age = 25.8 [4.33] years, mean [SD] BMI = 22
[3]) and six migraine without aura patients (5 women,
mean [SD] age = 24.3 [4.42] years, mean [SD] BMI = 20
[3]) between 18 and 50 years of age were recruited
through advertisement.
Trained researchers screened all participants for their eli-
gibility. The participants then underwent a medical examin-
ation by the neurologist and psychiatrist researchers.
Exclusion criteria were current or past serious medical,
major psychiatric or neurologic disorders and left-
handedness, use of daily medication except contracep-
tives, and in case of migraine patients the use of prevent-
ive medications. Mini-International Neuropsychiatric
Interview (M.I.N.I.) was used to exclude any mental dis-
orders [28]. Volunteers who had any history of excessive
alcohol consumption or psychotropic medication use
were also excluded. All participants were asked to refrain
from caffeine intake for 4 h and from alcohol intake for
24 h prior to the MRI sessions. All participants were
pain- and medication-free in the preceding 48 h before
each scanning session.
The diagnosis of migraine without aura was made by
neurologist researchers according to the International
Headache Society criteria [29]. The study was approved
by the Scientific and Research Ethics Committee of the
Medical Research Council, Budapest, Hungary. After re-
ceiving written and oral information all subjects gave
written informed consent. The study was carried out in
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accordance with the principles of Declaration of
Helsinki.
Headache characteristics of the participants
Participants with migraine without aura: The mean dur-
ation of the disorder [SD] was 11 years [4.56] with mean
number of migraine attacks per month [SD] = 4.75 [2.99].
Three of six patients used sumatriptan. All migraine pa-
tients used analgesics including metamizole, ibuprofen,
paracetamol, diclofenac, or paracetamol –propyphenazone
– caffeine containing combined tablet for treating their
headaches, and 2 of them also used domperidon to pre-
vent nausea and vomiting. All of the migraine patients re-
ported occasional tension type headaches. None of the
migraine subjects suffered from medication-overuse head-
ache and/or chronic migraine. The mean [SD] time of the
preceding migraine attack before the placebo scans was 6
[3.6] days, and before the citalopram scans was 9 [4.7]
days. All migraine patients were headache- and
medication-free in the preceding 48 h before each scan-
ning session.
Healthy controls
All healthy participants reported less than 12 mild ten-
sion type headache per year with no migraine type
symptoms.
Experimental design
All subjects attended two 30 min-lasting phMRI scan-
ning sessions, separated by at least 2 weeks. Anatomical
datasets were acquired during the first occasion. During
phMRI sessions all subjects received placebo (normal sa-
line) or 7.5 mg citalopram infusion in a double-blind,
randomized, balanced order design. All subjects were
cannulated at least 45 min before they entered the scan-
ner. A 10 min saline infusion was followed by a saline or
citalopram infusion which lasted for 7.5 min. In the
remaining time a saline infusion was used to keep vein
open. In the scanner all participants rested viewing a
blank screen and they received yes/no questions every 5
min to monitor their current state. Participants could re-
spond with button press (1 = yes, 2 = no) for the state-
ments: anxious, drowsy, lightheaded, nauseous, restless
and uncomfortable.
Data acquisition
Functional dataset acquisition was performed on a 3
Tesla MRI scanner (Achieva 3 T, Philips Medical Sys-
tem) using a T2*-weighted echo-planar (EPI) pulse-
sequence (TR = 2.500 ms, TE = 30 ms, FOV: 240 × 240
mm2 and with 3x3x3 mm resolution) using an eight-
channel SENSE head coil. Anatomical images were ac-
quired using a 3D T1-weighted turbo field echo (TFE)
sequence and 1x1x1 mm resolution.
Subjective state data analysis
The subjective states in the healthy and patient groups
were analysed in SPSS 25 (IBM Corp. SPSS Statistics for
Windows, Version 25.0) using Wilcoxon signed-rank
tests and Mann-Whitney tests to determine any differ-
ences between the control and patient groups at p < 0.05
significance level.
fMRI data analysis
Imaging data analysis was performed using Statistical
Parametric Mapping (SPM 12, Friston, The Welcome
Department of Cognitive Neurology, London, UK). All
images were realigned using the first image as reference,
then these images were spatially normalised into stereo-
tactic MNI space and then smoothed with a Gaussian
kernel of 8 mm FWHM.
ARtifact detection Tools (ART) toolbox (http://www.
nitrc.org/projects/artifact_detect/) for SPM was used to
determine movement artefacts in the scanner. We de-
fined outliers as time points in which global signal devi-
ated more than 3 SDs from the mean or motion to any
direction that exceeded 1 mm deviation. Exclusion cri-
teria was more than 15% of outliers in the whole session.
All patients and healthy controls satisfied these criteria.
During first level analysis the phMRI scans were di-
vided into 30 consecutive 1 min time-bins (T01 to T30;
the 1 min time bins were used to investigate the activa-
tion changes over time due to the drug challenge). The
images were then normalised by subtraction of the T01
time bin from the other 29 time bins (T02-T30) and the
images were then controlled for signal drift using a non-
linear model of the drift. The time-bin images for the sa-
line scans were then subtracted from the corresponding
time-bins for the citalopram scans. The baseline time-
bin (T10, as it is not biased by the signal variations in
the first 10 min before citalopram administration) and
T11-T30 post-infusion time bins were then entered into
a 2 by 21 repeated measures ANOVA with time as a re-
peated measure factor and diagnosis as a grouping fac-
tor. We investigated the time by treatment by group
interaction in the ACC, defined according to the Talair-
ach Daemon (TD) atlas label that contains both left and
right ACC. Results are reported at a small volume cor-
rected peak level threshold of Family Wise Error cor-
rected p(FWE) < 0.05.
Results
Behavioral and migraine related data
The number of ‘yes’ answers to questions about current
subjective state did not differ significantly between the
saline and citalopram challenge according to the Wil-
coxon test in 27 healthy subjects and in 6 migraine with-
out aura patients (Table 1.).
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Mann-Whitney tests showed no significant difference
between the two groups in neither subjective answers
during citalopram phMRI sessions (Table 2.).
No migraine patients experienced headache during the
scanning sessions. No subject reported headache after
citalopram session in the following 72 h. Two subjects
reported migraine attack 24 and 48 h after placebo
session.
Citalopram challenge phMRI
We found significant difference in ACC activation be-
tween control and patient groups in two peaks in the
right pregenual ACC (pgACC) during and after citalo-
pram infusion compared with placebo. In addition, a
trend of significant difference between groups was found
in the left pregenual part of rostral ACC (Table 3.). The
extracted time-series showed that the activation of ACC
increased in migraine patients compared to controls, es-
pecially in the first 8–10 min after the beginning of the
citalopram infusion.
Blood oxygen level dependent (BOLD) signal changes
over time are illustrated for the three pgACC cluster
peaks in Fig. 1.
Discussion
In this pilot study, using citalopram phMRI we demon-
strated a significant difference in temporal activation
pattern of the ACC between healthy control participants
and migraine without aura patients during the acutely
increased extracellular 5-HT level in the brain. The
intravenous citalopram elicited increased activation over
time in two peaks within the pregenual part of the right
ACC in migraine patients when compared to healthy
controls. This increased activation in migraine subjects
was more pronounced in the first 10 min after the start
of the citalopram. In addition, increased activation was
found in one cluster in the left rostral ACC in migraine
patients. Though this latter activation did not survive
the correction for multiple comparisons, our results
suggests a bilateral effect of increased brain 5-HT level
on the ACC in the migraine patients.
The altered functions of the pgACC in migraine have
been reported in previous fMRI studies. Increased acti-
vation was found in migraine patients to trigemino-
nociceptive stimulation compared to controls also in the
rostral part of the ACC [30]. Emphasizing the import-
ance of our results, previous fMRI studies using trigemi-
nal heat stimulation to induce acute pain in migraine
patients, found increased brain activation in the pgACC
with almost identical MNI coordinates as reported here
[8, 31]. One of these studies showed that this enhanced
activation to noxious heat reduced after a 60 day suc-
cessful treatment with external trigeminal neurostimula-
tion [31]. The authors suggested that the pgACC could
be involved in the antinociceptive effect of the anti-
migraine treatment [31]. Our results are in line with
these results as we found that this region is more active
in migraine patients after a small increase of 5-HT levels
compared to pain-free healthy controls. These observa-
tions together suggest that increased sensitivity of the
ACC in migraine patients might be related to altered se-
rotonergic control of the incoming excitatory signals.
According to literature the most consistently reported
area of cingulate cortex to painful stimuli is the dorsal
ACC or anterior middle cingulate cortex (aMCC). The
activation of this area is one of the earliest responses to
pain as this region has an impact in cortical nociception
[32]. A recent meta-analysis showed a significant likeli-
hood of activation to painful stimuli in this brain area in
healthy subjects [33]. In case of our study we did not
find any activation of this area, however, we have not
used any painful stimuli during the scanning sessions
and we investigated the difference between migraine pa-
tients and healthy controls.
On the basis of the functional imaging studies of the
last 20 years, the role of pgACC in many aspects of emo-
tional processing seems to be established. In a PET study
the pgACC was active during the assessment of internal
Table 1 The results of Wilcoxon signed-rank test of ‘yes’ answers to questions about subjective states between citalopram and
placebo sessions in control subjects (CO) and migraine patients (M)
Anxious Drowsy Lightheaded Nauseous Restless Uncomfortable
Z p Z p Z p Z p Z p Z p
CO −1.069 0.285 −1.212 0.226 −1.826 0.068 −1.633 0.102 −0.197 0.844 −0.104 0.917
M 0.000 1.000 −1.265 0.206 −1.342 0.180 −1.342 0.180 −1.272 0.785 0.000 1.000




Anxious Drowsy Lightheaded Nauseous Restless Uncomfortable
Z p Z p Z p Z p Z p Z p
Diagnoses −0.471 0.637 −0.688 0.492 −1.214 0.225 −1.347 0.178 −0.258 0.796 −1.553 0.121
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emotional state induced by emotional pictures with dif-
ferent valences [34]. Another study with fMRI showed
that the subjective ratings of pleasantness or aversiveness
of sensory stimuli correlated with the activation of this
area during a decision making task [35]. In addition, the
pregenual part of ACC is a central node of the default
mode network, a task-negative network that is consist-
ently active during mind-wandering and it is implicated
in the affective network [36]. The pgACC is the only
area in the cingulate gyrus that has connection with
all other regions of the cingulate cortex therefore this
ACC subregion could be considered as the anterior
cingulate association area [36], which is involved –
along with other brain areas – in integrating informa-
tion across the brain [37]. These observations point
to the essential role of the pgACC in emotional pro-
cessing, specifically in emotional awareness, e.g. the
fundamental role of this area for individuals to assess
their own emotional experience [38]. Thus, our re-
sults may suggest that migraine patients have exagger-
ated responses to interoceptive, e.g. emotional or
visceroceptive stimuli that might be related to altered
serotonergic neurotransmission in migraine. However,
taking into account the rich brain network of the
pgACC further studies are needed to determine
whether the increased 5-HT level in the brain directly
sensitizes the pgACC in migraineurs or the increased
activation of the ACC is secondary to a complex
interplay between the increased 5-HT level and those
subcortical and other cortical areas that are important
Table 3 ROI analysis results of control versus patient groups
comparison in the citalopram minus placebo data at p < 0.001
uncorrected height threshold. (*significant clusters after Family
Wise Error correction at p(FWE) < 0.05 secondary threshold; k =
number of voxels)
MNI coordinates side k p(FWE) F
valuex y z
15 38 8 right 9 0.006 2.969*
9 41 −4 right 6 0.022 2.745*
−9 44 8 left 6 0.075 2.519
Fig. 1 BOLD signal changes over time after citalopram minus placebo data extraction in three clusters of the ACC with error bars (standard error
of mean), for control and patient groups, respectively. Coronal and sagittal view of ROI analysis results were made by p(FWE) < 0.05 secondary
threshold (with p < 0.001 primary threshold, k≥ 5, CO = control group, M =migraine group)
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in processing different sensory and interoceptive
signals.
Nevertheless, the pgACC is the ACC subregion with
the highest opioid receptor density [39] and it also plays
an important role in opioid analgesia and opioid placebo
effect [40]. In addition, the increased pgACC signal dur-
ing noxious stimuli may reflect the attention to unpleas-
antness of pain [41, 42]. The recurring headache attacks
and the increased attention to unpleasantness of pain in
migraine patients may cause altered pgACC functions.
Our results extend this observation and suggest that this
phenomenon might be related to altered serotonergic
neurotransmission in migraine.
A recent systematic review of electrophysiological and
neuroimaging studies of serotonergic system in migraine
confirmed the altered 5-HT neurotransmission which has
been a main area of interest in migraine research for de-
cades [43]. The authors supported the notion of suddenly
increasing 5-HT levels during migraine headache [43].
Based on our results we speculate that during migraine at-
tack the pgACC reacts to the spontaneously elevated 5-
HT levels the same way as in our study by citalopram
challenge i.e. with increased activation. If so, it may con-
tribute to the development of migraine attack by facilitat-
ing the pain transmission at the trigeminal level [44]
similarly to that observed at the spinal cord [10].
In line with previous studies, we can conclude that mi-
graine patients are more sensitive to acute increase in 5-
HT levels and that this phenomenon can be observed in
a subregion of the ACC which is involved in emotional
aspects and suffering elements of pain and may be
involved in the modulation and/or chronification of mi-
graine. However, the direction of the connection be-
tween migraine attacks and the steep increase of 5-HT
levels during headache remains unclear.
Interestingly, a previous study of peripherial neuro-
chemical changes in migraine showed that slight release
of platelet 5-HT after a nitroglycerin test could be pro-
tective against migraine development [19]. The authors
reported that no migraine attack developed in migraine
patients who responded with increased peripherial 5-HT
level to nitroglycerin [19]. However, this study investi-
gated only the peripherial changes of 5-HT level. In
addition, nitroglycerine induced migraine may develop
through other mechanisms than migraine attacks caused
by 5-HT releasing agents. As 5-HT releasing agents e.g.
reserpine can provoke migraine [24], it is possible that
migraine attacks caused by extensive increase in brain 5-
HT levels in sensitive patients may be related to the in-
creased activation and altered pain-modulation of the
pgACC.
Nevertheless, it has to be mentioned that none of our
6 migraine patients developed headache during or im-
mediately after the citalopram administration. As we
used a relatively low dose of citalopram the increase in
5-HT levels probably did not reach the level that occurs
during migraine attack.
Our major limitation in this study is the relatively low
number of participants in the patient group. Despite the low
sample size, we found significant activation difference be-
tween the two groups. It would be fruitful however to inves-
tigate the acute effect of 5-HT level changes on the ACC
activation in more migraine patients in the future to replicate
and confirm our results. It would be also important to inves-
tigate the activation differences between migraine patients
and controls in other important pain processing areas or
even in the whole brain with higher sample size.
Furthermore, it has to be mentioned that in contrast
to PET phMRI is not suitable to detect specific receptor
activation changes, therefore we were not able to deter-
mine which serotonergic receptor or receptors are re-
sponsible for the observed activation changes. However,
our aim was not to detect changes in receptor activation,
rather to investigate the general sensitivity to increased
5-HT levels in migraine.
In addition, we have not corrected our analysis for po-
tential individual differences of the grey matter density
in the ACC that might influence the BOLD signal
changes.
Finally, in spite of the fact that the pgACC is highly in-
volved in emotional processing, we did not find any differ-
ence between citalopram and placebo sessions and between
migraine and control groups in the subjective states. Thus,
the difference between the two groups to citalopram could
not be detected at subjective behavioral level, only at neural
level. However, the lack of changes at behavioral level could
be related to the dichotomous characteristic of the answers
or to the relatively low dosage of citalopram.
Conclusions
In conclusion, our findings confirmed the increased sen-
sitivity to elevated 5-HT and the altered functions of the
ACC in interictal migraine patients compared to con-
trols. Our results demonstrate that a small increase in 5-
HT level leads to increased activation in the pregenual
part of the ACC which has been previously reported to
be involved in emotional aspects of pain. These observa-
tions suggest that the pgACC activation might also in-
creases during migraine attacks, which process might be
related to the suddenly increasing 5-HT levels, contrib-
uting to the suffering element of pain. The increased
sensitivity of the pgACC in migraine patients may also
contribute to the recurring migraine attacks and the in-
creased stress-sensitivity in migraine.
Finally, our study offers a new approach to investigate
the brain of migraine patients: we proved the acute cita-
lopram challenge is a suitable method to detect func-
tional alterations in migraine. This method could deepen
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our understanding about the pathophysiology of migraine
and even other neurologic or mental disorders in the fu-
ture that are related to altered 5-HT neurotransmission.
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